MetaCap

Aytu BioPharma (AYTU) vs Telomir Pharmaceuticals (TELO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aytu BioPharma (AYTU) has outperformed Telomir Pharmaceuticals (TELO) over the past year, gaining 32.3% versus a loss of 71.6%. Aytu BioPharma is the larger company by market cap ($28.9 million vs $26.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AYTU+32.34%TELO-71.56%
+50%-14%-77%
Nov 21, 20251 yearNov 20, 2026
AYTU-7.32%TELO-92.72%
+92%-5%-101%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AYTU versus TELO key metrics
MetricAYTUTELO
Share price$2.66$0.364
Market cap$28.91M$26.82M
1-day change0.00%-17.24%
YTD return+2.31%-72.63%
1-year return+32.34%-71.56%
5-year return-93.21%—
Forward P/E17.16—
EPS (TTM)$-1.78$-0.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$57.57M—
Revenue growth (YoY)-13.27%—
Net income (latest FY)$-14.25M$-10.41M
Gross margin63.95%—
Operating margin-14.44%—
Net margin-24.76%—
52-week high$3.07$1.58
52-week low$1.75$0.353
Distance from 52-week high-13.36%-76.96%
Analyst consensusstrong_buynone
Avg. price target upside+263.53%+998.90%
Average volume141.18K126.14K
Shares outstanding10.87M73.68M
Employees75—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AYTU has outperformed TELO by 103.9 percentage points over the past year.

About Aytu BioPharma

AYTU stock →

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About Telomir Pharmaceuticals

TELO stock →

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.

Health Care · Biotechnology: Pharmaceutical Preparations

AYTU vs TELO FAQ

Which is bigger, Aytu BioPharma or Telomir Pharmaceuticals?

Aytu BioPharma (AYTU) is larger, with a market capitalization of $28.91M compared with $26.82M for Telomir Pharmaceuticals (TELO).

Which stock has performed better over the past year, AYTU or TELO?

AYTU returned +32.34% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.

Are Aytu BioPharma and Telomir Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons